Article

WaveLight attains 20% of U.S. refractive laser sales in 1 year

New Orleans-WaveLight Inc. announced that during the last 12 months, its Allegretto Wave laser achieved a 20% share of all new refractive laser sales in the United States.

"We consider our success in the U.S. market to be our greatest accomplishment to date," said Max Reindl, chief executive officer of WaveLight Laser Technologie AG. "Ophthalmologists and patients alike benefit from the Allegretto Wave's shorter treatment times, safety features, and unique ablation profile designed to minimize the induction of spherical aberrations during surgery. Strong demand for the Allegretto Wave validates our commitment to develop and introduce the most innovative technology in the marketplace."

In addition to acquiring a considerable presence within ophthalmology, WaveLight recently announced that its revenues have increased 30% for the fiscal year ending July 31, 2004. WaveLight attributes much of its financial performance to refractive laser sales.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.